The short answer
Metastatic bladder cancer means cancer has spread beyond its original site. Treatment may still help, but the plan depends on location, symptoms, biomarkers, prior care, and goals.
Stage IV covers two situations: a tumour grown into the pelvic or abdominal wall, and cancer that has spread to distant sites. Ask which one describes you.
Kidney function is a treatment decision here, not just a lab result, because it decides whether cisplatin is possible.
NCI's stage IV option list includes enfortumab vedotin plus pembrolizumab, chemotherapy plus immunotherapy, chemotherapy alone, and immunotherapy alone; the order on a list is not a ranking for your case.
Erdafitinib needs a specific test showing one of a defined set of FGFR changes; not every FGFR result counts, and the test is not part of routine pathology.
Choose how you want to understand this
The full explanation.
What stage IV bladder cancer means here
Most bladder cancer is urothelial carcinoma. Stage IV covers two different situations.
One is a tumor that has grown into the pelvic wall or abdominal wall but has not travelled. The other is cancer that has spread to distant sites.
NCI lists similar options for both, so ask which one describes you. It changes how surgery and radiation fit in.
The cisplatin question comes first
Cisplatin is hard on the kidneys. Not everyone can have it.
In one large NCI-cited trial, entry to the cisplatin arm required a creatinine clearance of at least 40 mL per minute. That figure is a trial eligibility rule, not the line your oncologist draws for you. Kidney function is genuinely one of the things that decides whether cisplatin is on the table, but so are hearing, nerve symptoms, heart function and how well you are overall.
NCI describes a separate group who are ineligible for cisplatin, and a smaller group ineligible for both cisplatin and carboplatin. Different drugs apply to each.
The combination at the top of NCI's list
For stage IV bladder cancer, NCI's option list opens with enfortumab vedotin plus pembrolizumab. Where something sits on a list is not a ranking of what is right for you, and this combination is not suitable for everyone: existing nerve damage, diabetes and skin conditions all weigh against it.
Chemotherapy plus immunotherapy comes next, then chemotherapy alone, then immunotherapy alone.
Side effects matter here. In the trial NCI cites, the most common severe problems with enfortumab vedotin plus pembrolizumab were skin reactions, nerve damage in the hands and feet, high blood sugar, and low white cells.
FGFR testing, and what it unlocks
Erdafitinib is a targeted drug for urothelial cancer. NCI describes the trial that led to it.
Patients had to have a tumour carrying one of a defined set of FGFR3 changes or FGFR2 or FGFR3 fusions. Not every FGFR change counts; the approved test defines which ones do. That is a specific test, not part of routine pathology, so ask whether it was run and exactly what it found.
Ask whether it has been sent, and how long the result takes.
If chemotherapy works, what holds it there
NCI reports a survival benefit from maintenance avelumab. It was given after platinum-based chemotherapy, in people whose cancer had not progressed during it.
In that trial, chemotherapy was gemcitabine with either cisplatin or carboplatin, for four to six cycles.
Ask whether maintenance is planned, and when the switch would happen.
Questions for the urologic oncology team
- Is my cancer locally advanced, or has it spread to distant organs?
- What is my creatinine clearance, and does it allow cisplatin?
- Would you start enfortumab vedotin with pembrolizumab, and why or why not?
- Has my tumor been tested for an FGFR3 change or an FGFR2 to FGFR3 fusion?
- If chemotherapy works, would maintenance avelumab start straight afterward?
- My bladder is bleeding, or a kidney is backing up. What can relieve that now?
- What is left after platinum and immunotherapy, and is a trial open here?
Comfort is part of the plan, not a fallback
NCI's stage IV list includes radiation for palliation, and urinary diversion or bladder removal for palliation.
Those are on the treatment list, not after it. Ask for them when symptoms are the problem.
When to get help sooner
- Call 911 or go to an emergency department if you cannot pass urine at all, or you are passing large blood clots and the flow keeps blocking. Go too if bleeding comes with dizziness or fainting, or if you have severe breathlessness or chest pain.
- A temperature of 100.4°F (38°C) or higher, or chills, means emergency care the same hour. Chemotherapy and enfortumab vedotin both leave you more open to infection, so do not wait for a same-day slot or a call back; CDC treats a fever during chemotherapy as a medical emergency. Mention a spreading rash or peeling skin on enfortumab vedotin when you get there. If your team has given you a written plan for this regimen, follow it and take it with you.
- Call your care team the same day if you have pain in your side or back with much less urine than usual, which can mean a kidney is backing up. If you are on enfortumab vedotin, call the same day for a spreading rash, blistering or peeling skin, or sores in your mouth or eyes. Severe skin reactions with this drug can be life threatening, and most start in the first cycle. Also call the same day for heavy thirst, passing lots of urine, or confusion, which can mean high blood sugar, and for a new cough or breathlessness.
- Call your care team within a day or two if numbness, tingling or weakness in your hands or feet is new or getting worse, or if your eyes are dry, sore, or your vision has changed. Do the same for burning on passing urine, or blood in the urine that is new but light.
Related pages
Useful next: Cancer Staging, Biomarker Testing, Palliative Care, and Questions to Ask Your Doctor.
Where this comes from
- NCI PDQ - Bladder Cancer Treatment (Patient Version)
- NCI PDQ - Bladder Cancer Treatment (Health Professional Version)
- DailyMed - PADCEV (enfortumab vedotin) label: skin reactions, hyperglycemia, pneumonitis, peripheral neuropathy, ocular disorders
- NCI - Infections and Neutropenia during Cancer Treatment
Words to know
Tap any term to see what it means.
Common questions
Why does my kidney function decide the plan?
Because cisplatin is hard on the kidneys and not everyone can have it. In one large trial NCI cites, the entry rule for the cisplatin arm was a creatinine clearance of at least 40 mL per minute. That was a trial eligibility line, not a clinical cut-off your team applies to you; fitness, hearing, nerve symptoms and heart function all weigh in as well. NCI describes a separate group ineligible for cisplatin, and a smaller group ineligible for both cisplatin and carboplatin, with different drugs for each.
What options does NCI list for stage IV?
Enfortumab vedotin plus pembrolizumab, chemotherapy plus immunotherapy, chemotherapy alone, and immunotherapy alone. The order they are printed in is not a ranking; what suits you depends on your kidney function, nerve symptoms, diabetes, skin, and how fast the disease is moving. In the trial NCI cites, the most common severe problems with enfortumab vedotin plus pembrolizumab were skin reactions, nerve damage in the hands and feet, high blood sugar, and low white cells.
If chemotherapy works, what keeps it working?
NCI reports a survival benefit from maintenance avelumab given after platinum-based chemotherapy in people whose cancer had not progressed during it. In that trial the chemotherapy was gemcitabine with either cisplatin or carboplatin, for four to six cycles. Ask whether maintenance is planned and when the switch would happen.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Your next step
Turn this topic into questions for your next appointment.
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Sources last checked: 2026-08-13 what this meansLast updated: 2026-08-19Next planned review: 2027-07-30
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
High-risk topic — talk to your care team. This topic can involve urgent, individual medical decisions. This page is general education only: it cannot tell you whether your situation is an emergency or what you personally should do. Follow your oncology team's instructions and contact them for individual guidance.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share